Amongst these was the FOXA1 locus, which has been reported to harbor coding point mutations in ∼3% of localized tumors (13), 3′ UTR indels in an estimated ∼9% of metastatic tumors (40), and frequent structural rearrangements (∼11 to ∼35%) across a spectrum of primary and advanced disease (41, 42). Here, FOXA1 is linked to metastatic neoplasm.